Published in Ann Intern Med on January 15, 1990
Current and emerging azole antifungal agents. Clin Microbiol Rev (1999) 5.70
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Coccidioidomycosis: a reemerging infectious disease. Emerg Infect Dis (1996) 2.35
Coccidioidomycosis. West J Med (1993) 1.79
The public health impact of coccidioidomycosis in Arizona and California. Int J Environ Res Public Health (2011) 1.35
Endemic mycoses in AIDS: a clinical review. Clin Microbiol Rev (1995) 1.20
Cost-effectiveness of a potential vaccine for Coccidioides immitis. Emerg Infect Dis (2001) 0.97
Comparison of fluconazole and itraconazole in a rabbit model of coccidioidal meningitis. Antimicrob Agents Chemother (2000) 0.97
Reflections on the approach to treatment of a mycologic disaster. Antimicrob Agents Chemother (2013) 0.96
Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev (2011) 0.92
What can we learn and what do we need to know amidst the iatrogenic outbreak of Exserohilum rostratum meningitis? Clin Infect Dis (2013) 0.88
Comparison of SCH 39304 and its isomers, RR 42427 and SS 42426, for treatment of murine cryptococcal and coccidioidal meningitis. Antimicrob Agents Chemother (1992) 0.83
A phenome-guided drug repositioning through a latent variable model. BMC Bioinformatics (2014) 0.78
Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis. Antimicrob Agents Chemother (2006) 0.76
Antifungal therapy: from amphotericin B to present. Trans Am Clin Climatol Assoc (1993) 0.75
Systemic antifungal agents. Tex Heart Inst J (1990) 0.75
Application of DNA typing methods to epidemiology and taxonomy of Candida species. J Clin Microbiol (1987) 13.21
Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis (2001) 12.73
Antimicrobial susceptibility testing of yeasts: a turbidimetric technique independent of inoculum size. Antimicrob Agents Chemother (1976) 8.54
A Candida albicans dispersed, repeated gene family and its epidemiologic applications. Proc Natl Acad Sci U S A (1988) 7.75
Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis (1991) 6.43
Turbidimetric studies of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods. Antimicrob Agents Chemother (1978) 5.94
Direct allelic variation scanning of the yeast genome. Science (1998) 5.90
Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) (2000) 4.98
Recognition by pregnancy serums of non-HL-A alloantigens selectively expressed on B lymphocytes. J Exp Med (1975) 4.96
Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother (1997) 4.75
Correlation of in vitro susceptibility test results with in vivo response: flucytosine therapy in a systemic candidiasis model. J Infect Dis (1983) 4.42
Miconazole in coccidiodomycosis. II. Therapeutic and pharmacologic studies in man. Am J Med (1976) 3.91
Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States. Antimicrob Agents Chemother (1982) 3.91
Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother (1982) 3.90
Treatment of invasive aspergillosis with itraconazole. Am J Med (1989) 3.87
Mouse model of pulmonary blastomycosis: utility, simplicity, and quantitative parameters. Am Rev Respir Dis (1978) 3.75
Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis (2000) 3.70
Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med (1991) 3.69
Ketoconazole, an oral antifungal: laboratory and clinical assessment of imidazole drugs. Postgrad Med J (1979) 3.55
The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells. J Exp Med (1991) 3.35
Laboratory diagnosis of invasive aspergillosis. Lancet Infect Dis (2005) 3.31
Nomenclature for factors of the HLA system, 2010. Tissue Antigens (2010) 3.22
Two genes encoding steroid 21-hydroxylase are located near the genes encoding the fourth component of complement in man. Proc Natl Acad Sci U S A (1985) 3.22
Standardized susceptibility testing of fluconazole: an international collaborative study. Antimicrob Agents Chemother (1992) 3.19
Two HLA-linked loci controlling the fourth component of human complement. Proc Natl Acad Sci U S A (1978) 3.05
In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother (1997) 2.99
Miconazole in coccidioidomycosis. I. Assays of activity in mice and in vitro. J Infect Dis (1975) 2.99
Variability of agar dilution-replicator method of yeast susceptibility testing. Antimicrob Agents Chemother (1979) 2.84
Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus. Antimicrob Agents Chemother (1997) 2.79
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A (2000) 2.79
Restriction endonuclease analysis of total cellular DNA of Aspergillus fumigatus isolates of geographically and epidemiologically diverse origin. J Infect Dis (1990) 2.66
Close genetic linkage between HLA and congenital adrenal hyperplasia (21-hydroxylase deficiency). Lancet (1978) 2.66
Lymphocyte interferon production and transformation after Herpes simplex infections in humans. J Immunol (1974) 2.64
HLA-linked congenital adrenal hyperplasia results from a defective gene encoding a cytochrome P-450 specific for steroid 21-hydroxylation. Proc Natl Acad Sci U S A (1984) 2.56
The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells in vitro. J Clin Invest (1992) 2.51
Aspergillus flavus: human pathogen, allergen and mycotoxin producer. Microbiology (2007) 2.49
Adverse events associated with itraconazole in 189 patients on chronic therapy. J Antimicrob Chemother (1990) 2.49
Laboratory and clinical assessment of ketoconazole in deep-seated mycoses. Am J Med (1983) 2.45
High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet (1985) 2.44
Genetic characterization of pathogenic Saccharomyces cerevisiae isolates. Genetics (1994) 2.41
In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis (1992) 2.41
Histocompatibility determinants in multiple sclerosis, with special reference to clinical course. Lancet (1973) 2.41
Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect (2011) 2.38
Review of nocardial infections in France 1987 to 1990. Eur J Clin Microbiol Infect Dis (1992) 2.36
Structure of human steroid 21-hydroxylase genes. Proc Natl Acad Sci U S A (1986) 2.34
Analysis of Candida albicans phenotypes from different geographical and anatomical sources. J Clin Microbiol (1983) 2.33
Individual and environmental factors associated with infection due to Cryptococcus neoformans serotype D. French Cryptococcosis Study Group. Clin Infect Dis (1996) 2.33
Mechanisms and clinical impact of antifungal drug resistance. J Med Vet Mycol (1994) 2.32
Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med (1982) 2.25
The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis (2001) 2.25
Effect of cyclodextrin on the pharmacology of antifungal oral azoles. Antimicrob Agents Chemother (1992) 2.22
High prevalence of antifungal resistance in Candida spp. from patients with AIDS. J Antimicrob Chemother (1994) 2.21
The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol (2005) 2.21
Galactomannan antigenemia and antigenuria in aspergillosis: studies in patients and experimentally infected rabbits. J Infect Dis (1987) 2.18
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study. Ann Intern Med (1983) 2.17
Molecular and phenotypic characterization of genotypic Candida albicans subgroups and comparison with Candida dubliniensis and Candida stellatoidea. J Clin Microbiol (1999) 2.15
Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect (2004) 2.13
Treatment of mycoses with itraconazole. Ann N Y Acad Sci (1988) 2.11
Fluconazole resistance in Candida in patients with AIDS--a therapeutic approach. J Infect (1993) 2.10
Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob Agents Chemother (1997) 2.07
Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. J Clin Microbiol (1993) 2.06
Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob Agents Chemother (1998) 2.04
Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy (2013) 2.03
Epidemiology of cryptococcosis in France: a 9-year survey (1985-1993). French Cryptococcosis Study Group. Clin Infect Dis (1996) 2.02
Itraconazole therapy for blastomycosis and histoplasmosis. NIAID Mycoses Study Group. Am J Med (1992) 2.01
Antifungal drug resistance in Aspergillus. J Infect (2000) 2.01
Ketoconazole blocks testosterone synthesis. Arch Intern Med (1982) 2.01
Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole. Chest (1991) 2.00
Nomenclature for factors of the HLA system, 1990. Tissue Antigens (1991) 1.98
Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood (2001) 1.98
Fluconazole-resistant candidosis in an HIV cohort. AIDS (1994) 1.95
Visceral fungal infections due to Petriellidium boydii (allescheria boydii). In vitro drug sensitivity studies. Am J Med (1976) 1.93
Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med (1996) 1.91
Trichosporon on humans: a practical account. Mycoses (1994) 1.90
Nomenclature for factors of the HLA system, 2002. Tissue Antigens (2002) 1.89
Cloning and expression of cDNA encoding a bovine adrenal cytochrome P-450 specific for steroid 21-hydroxylation. Proc Natl Acad Sci U S A (1984) 1.89
A common pathway for T lymphocyte activation involving both the CD3-Ti complex and CD2 sheep erythrocyte receptor determinants. J Immunol (1986) 1.88
Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J (2010) 1.87
Distribution of a corticosteroid-binding protein in Candida and other fungal genera. J Gen Microbiol (1983) 1.86
Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulation of transferrin receptor expression. J Immunol (1985) 1.86
Invasive aspergillosis in patients with acquired immunodeficiency syndrome: report of 33 cases. French Cooperative Study Group on Aspergillosis in AIDS. Am J Med (1993) 1.86
Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol (2001) 1.85
Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrob Agents Chemother (1988) 1.85
Chido and Rodgers blood groups are distinct antigenic components of human complement C4. Nature (1978) 1.85
A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis (2001) 1.84
Hydrocortisone-enhanced growth of Aspergillus spp.: implications for pathogenesis. Microbiology (1994) 1.82
Recombinant and natural gamma-interferon activation of macrophages in vitro: different dose requirements for induction of killing activity against phagocytizable and nonphagocytizable fungi. Infect Immun (1985) 1.82
Efficacy of SCH39304 and fluconazole in a murine model of disseminated coccidioidomycosis. Antimicrob Agents Chemother (1990) 1.81
Invasive aspergillosis in patients with AIDS. Clin Infect Dis (1994) 1.80
Serotyping of Cryptococcus neoformans by using a monoclonal antibody specific for capsular polysaccharide. J Clin Microbiol (1993) 1.80
Multicenter evaluation of the reproducibility of the proposed antifungal susceptibility testing method for fermentative yeasts of the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antimicrobial Susceptibility Testing (AFST-EUCAST). Clin Microbiol Infect (2003) 1.79
Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab (1983) 1.77
Postexposure varicella management of nonimmune personnel: an alternative approach. Infect Control Hosp Epidemiol (1994) 1.77
Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with AIDS. Clin Infect Dis (1993) 1.76
Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med (1989) 1.76